<DOC>
	<DOC>NCT01266434</DOC>
	<brief_summary>To test whether simvastatin has an additional anti-inflammatory effects on p38 MAPK, a signaling molecule for inflammation in inhaled steroid-treated asthmatics.</brief_summary>
	<brief_title>The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids on p38 MAPK in Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>mildtomoderate persistent asthmatics FEV1 = OR &gt; 50% of predicted Previous history of renal disease or serum creatinine is more than 2 mg/dl. Previous history of liver disease. Pregnancy or lactation. Are already receiving or are known to be allergic to statins or to have developed myositis. Have an asthma exacerbation requiring treatment with oral corticosteroids during the 3 months prior to the commencement of study entry. Being treated with immunosuppressive agents. Unwilling to cooperate the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>moderate persistent asthma</keyword>
	<keyword>Inhaled corticosteroids</keyword>
</DOC>